mk2 Biotechnologies

Munchen, Germany Founded: 2017 • Age: 9 yrs
Peptides and proteins are developed for life science applications.

About mk2 Biotechnologies

mk2 Biotechnologies is a Healthcare company based in Munchen (Germany) founded in 2017 by Marco Giuman and Sebastian Mangold. Peptides and proteins are developed for life science applications. Its chief executive, as recorded, is Konstantinos Antonopoulos. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Proteomics. Its legal entity is mk2 Biotechnologies GmbH.

Company details

mk2 Biotechnologies was founded in 2017 in Munich, Germany, within the biotechnology sector. A scalable technology for peptide and protein synthesis is utilized, relying on recombinant methods to support production across various chain lengths. Services are provided to clients in research, development, agriculture, and stock breeding, facilitating applications in these fields. Operations focus on enabling large-scale manufacturing for life science needs.

  • Headquarters Munchen, Germany
  • Founders Marco Giuman, Sebastian Mangold
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website mk2.bio
  • Social LinkedIn
  • Legal Name Mk2 Biotechnologies Gmbh
Key Metrics

Funding Insights of mk2 Biotechnologies

  • Total Rounds 1
  • Investors Count 3

All 1 funding rounds of mk2 Biotechnologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2021Seed–OCCIDENT – The Science Investor.
Valuation history

3 investors in total: 3 institutional.

Investors in mk2 Biotechnologies

mk2 Biotechnologies has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include SeedBlink, Gateway Ventures and OCCIDENT.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital investments are provided to deep-tech startups.
occident.groupMunich, Germany
An online platform is operated for crowdfunding investments in startups.
2015gateway.venturesVienna, Austria
Investments in pre-seed and seed-stage startups are facilitated for individuals.
2019seedblink.comBucharest, Romania
Premium access

Investor details for mk2 Biotechnologies

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of mk2 Biotechnologies

7 people are tracked at mk2 Biotechnologies (5 in leadership, 2 in team).

NameRoleGroup
Marco Giuman
Co-Founder & CTOLeadership
Sebastian Mangold
Co-Founder & Managing DirectorLeadership
Konstantinos Antonopoulos
CEOLeadership
Kritan Gautam
Head Of Research & DevelopmentLeadership
Patrick Wiesbeck
Head Of Science & InnovationLeadership
Oliver Piech
Science & Innovation ManagerTeam
Viola Kallfaß
Development SpecialistTeam
Premium access

Complete people profiles for mk2 Biotechnologies

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of mk2 Biotechnologies

2 dated milestones of mk2 Biotechnologies across 4 years, from founding to its latest funding, stage changes and deals.

  1. Founded mk2 Biotechnologies is founded.
  2. Funding First funding round.

Web traffic of mk2 Biotechnologies

Websites that share an audience with mk2 Biotechnologies (mk2.bio).

Similar websites

Websites whose visitors overlap most with mk2 Biotechnologies. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
leukocare.com
100%
5.7K#3,715,251View details
project-pharmaceutics.com
100%
View details
amicusrx.de
amicusrx.de
99%
#10,724,948–
viramed.de
99%
View details
scirhom.com
98%
View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 19 similar websites and full traffic analytics for mk2 Biotechnologies

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 19 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about mk2 Biotechnologies

mk2 Biotechnologies was founded in 2017 and raised its 1st funding round 4 years after it was founded.

mk2 Biotechnologies is headquartered in Munchen, Germany. It is registered at Munchen, Bayern, Germany.

Konstantinos Antonopoulos is the CEO of mk2 Biotechnologies, as recorded in our data.

mk2 Biotechnologies was founded in 2017 in Munich, Germany, within the biotechnology sector. A scalable technology for peptide and protein synthesis is utilized, relying on recombinant methods to support production across various chain lengths. Services are provided to clients in research, development, agriculture, and stock breeding, facilitating applications in these fields. Operations focus on enabling large-scale manufacturing for life science needs.

mk2 Biotechnologies has 3 investors. Key investors include SeedBlink, Gateway Ventures, and OCCIDENT.

mk2 Biotechnologies operates through Mk2 Biotechnologies Gmbh.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available